MedTrace Logo

Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

NCT03707847 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-10-16

No results posted yet for this study

Summary

To observe the safety, tolerability and clinical effects of crizotinib combined with etoposide capsule followed by autologous hematopoietic stem cell transplantation (Auto-HSCT) for patients with relapsed and refractory ALK-positive Anaplastic Large Cell Lymphoma.

Conditions

  • ALK-Positive Anaplastic Large Cell Lymphoma

Interventions

DRUG

Crizotinib

250mg, BID, PO

DRUG

Etoposide Capsule

50mg, QD, PO, d1-10，21days for one cycle

PROCEDURE

Auto-HSCT

Auto-HSCT will be performed with patients who have achieved CR or VGPR.

Sponsors & Collaborators

  • Mingzhi Zhang

    lead OTHER

Principal Investigators

  • Mingzhi zhang · The First Affiliated Hospital of Zhengzhou University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-02-01
Completion
2021-02-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03707847 on ClinicalTrials.gov